Scott Brownstein, MD
Cardiovascular Disease · Upton, MANPI 1962471524
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 60.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $189 and has fallen 63.7% since, to $68 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in MA, where the typical reported total is $954.
Across 24 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$345
- Medtronic$121
- Johnson & Johnson$63
- Esperion Therapeutics, Inc.$20
- Angiodynamics, Inc.$17
What the payments were for
- Food & beverage$567100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 15 | $345 |
| Medtronic | 5 | $121 |
| Johnson & Johnson | 2 | $63 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Angiodynamics, Inc. | 1 | $17 |
How this compares
$567 in reported general payments places this provider in the 40th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $45,789 |
| Ezetimibe | 18 | $711 |
| Rosuvastatin Calcium | 18 | $621 |
| Atorvastatin Calcium | 30 | $568 |
| Losartan Potassium | 24 | $307 |
| Metoprolol Succinate | 20 | $298 |
| Amlodipine Besylate | 16 | $115 |
| Lisinopril | 11 | $81 |
| Spironolactone | 11 | $68 |
| Metoprolol Tartrate | 11 | $57 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Upton
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- Kevin CroceChestnut Hill$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.